Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor

被引：0
|
作者：
Wilson, Timothy R. [1 ]
Savage, Heidi [1 ]
O'Brien, Carol [1 ]
Sanabria, Sandra [1 ]
Lin, Ray S. [1 ]
Wagle, Marie-Claire [1 ]
Yan, Yibing [1 ]
Lackner, Mark R. [1 ]
Parmar, Hema [1 ]
Hsu, Jerry Y. [1 ]
Juric, Dejan [2 ]
Krop, Ian E. [3 ]
Ramanathan, Ramesh K. [4 ]
Von Hoff, Daniel D. [4 ]
Baselga, Jose [5 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Virginia G Piper Canc TGen, Scottsdale, AZ USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-915
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
915
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Schram, Alison M.
    Gandhi, Leena
    Mita, Monica M.
    Damstrup, Lars
    Campana, Frank
    Hidalgo, Manuel
    Grande, Enrique
    Hyman, David M.
    Heist, Rebecca S.
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1471 - 1476
  • [42] A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.
    Von Hoff, D. D.
    LoRusso, P.
    Demetri, G. D.
    Weiss, G. J.
    Shapiro, G.
    Ramanathan, R. K.
    Ware, J. A.
    Raja, R.
    Jin, J.
    Levy, G. G.
    Mazina, K. E.
    Wagner, A. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Alison M. Schram
    Leena Gandhi
    Monica M. Mita
    Lars Damstrup
    Frank Campana
    Manuel Hidalgo
    Enrique Grande
    David M. Hyman
    Rebecca S. Heist
    [J]. British Journal of Cancer, 2018, 119 : 1471 - 1476
  • [44] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Geoffrey I. Shapiro
    Patricia LoRusso
    Eunice Kwak
    Susan Pandya
    Charles M. Rudin
    Carla Kurkjian
    James M. Cleary
    Mary Jo Pilat
    Suzanne Jones
    Alex de Crespigny
    Jill Fredrickson
    Luna Musib
    Yibing Yan
    Matthew Wongchenko
    Hsin-Ju Hsieh
    Mary R. Gates
    Iris T. Chan
    Johanna Bendell
    [J]. Investigational New Drugs, 2020, 38 : 419 - 432
  • [45] Changes in plasma components β-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K)
    Ang, Joo Ern
    Pandher, Rupinder
    Asad, Yasmin
    Henley, Alan
    Valenti, Melanie
    Box, Gary
    Brandon, Alexis de Haven
    Eccles, Suzan
    Workman, Paul
    de Bono, Johann S.
    Raynaud, Florence I.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [46] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Shunsuke Kondo
    Masaomi Tajimi
    Tomohiko Funai
    Koichi Inoue
    Hiroya Asou
    Vinay Kumar Ranka
    Volker Wacheck
    Toshihiko Doi
    [J]. Investigational New Drugs, 2020, 38 : 1836 - 1845
  • [47] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
  • [48] A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
    Wade, James Lloyd
    Langer, Corey J.
    Redman, Mary
    Aggarwal, Charu
    Bradley, Jeffrey D.
    Crawford, Jeffrey
    Miao, Jieling
    Griffin, Katie
    Herbst, Roy S.
    Kelly, Karen
    Gandara, David R.
    Papadimitrakopoulou, Vassiliki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] A PHASE I STUDY EVALUATING THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE ORAL PAN-PHOSPHOINOSITIDE-3 KINASE (PI3K) INHIBITOR GDC-0941
    Baird, R.
    Kristeleit, R.
    Sarker, D.
    Olmos, D.
    Sandhu, S.
    Levy, G. G.
    Mazina, K. E.
    Yan, Y.
    Ware, J.
    De Bono, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 170 - 171
  • [50] A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941
    Sarker, D.
    Kristeleit, R.
    Mazina, K. E.
    Ware, J. A.
    Yan, Y.
    Dresser, M.
    Derynck, M. K.
    De-Bono, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345